Printer Friendly

Thalassemia Therapeutic Pipeline Review H1 2015 Market Research Report.

DALLAS, March 26, 2015 /PRNewswire/ -- adds "Thalassemia - Pipeline Review, H1 2015" therapeutic market research report of 100 pages with latest updates, data and information to its online business intelligence library.

The report " Thalassemia - Pipeline Review, H1 2015 " provides comprehensive information on the therapeutic development for Thalassemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Thalassemia is the name of a group of genetic blood disorders. Thalassemia is passed down through families (inherited) in which the body makes an abnormal form of hemoglobin. The disorder results in excessive destruction of red blood cells, which leads to anemia. The two main forms of thalassemia are alpha thalassemia and beta thalassemia. In alpha thalassemia, at least one of the alpha globin genes has a mutation or abnormality. In beta thalassemia, the beta globin genes are the ones affected. Treatment for thalassemia major often involves regular blood transfusions and folate supplements. Complete report available at .

The report also reviews key players involved in the therapeutic development for Thalassemia and special features on late-stage and discontinued projects. Companies discussed in this report include Acceleron Pharma, Inc., Acetylon Pharmaceuticals, Inc., Acino Pharma AG, Alnylam Pharmaceuticals, Inc., Bluebird bio, Inc., Emmaus Medical, Inc., Errant Gene Therapeutics, LLC, Gamida Cell Ltd., Incyte Corporation, IRBM Science Park SpA, Isis Pharmaceuticals, Inc., Johnson & Johnson, Protagonist Therapeutics Inc., Sangamo BioSciences, Inc.

Drug Profiles discussed in this report include ACY-957, ALN-TMP, Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders, BB-305, BtX-13, CNTO-530, Gene Therapy for Sickle Cell Disease and Beta Thalassemia, Gene Therapy for Sickle Cell Disease and Thalassemia, glutamine, luspatercept, NiCord, PB-04, Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis, Project x-1450, ruxolitinib phosphate, Small Molecule to Inhibit Histone Deacetylase for Beta-Thalassemi, sotatercept, Stem Cell Therapy for Beta Thalassemia, Synthetic Peptides Hematological and Genetic Disorders, Thalagen. Order a Purchase copy of this report @ (This is a premium report priced at US$2000 for a single user License.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The scope of the report ranges from global therapeutic landscape of Thalassemia to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Featured news & press releases cover by this report include: Feb 04, 2015: Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of its Novel ZFP Therapeutic for Beta-Thalassemia; Dec 08, 2014: Acetylon Pharmaceuticals Presents Positive Preclinical Data on Selective HDAC1/2 Inhibition for the Treatment of Sickle Cell Disease/E-thalassemia; Dec 07, 2014: New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; Nov 06, 2014: Acceleron Announces New Clinical Data Presentations on luspatercept at the 2014 American Society of Hematology Annual Meeting; Nov 06, 2014: Celgene To Present Phase II trial Results Update On Luspatercept at American Society of Hematology Annual Meeting; Nov 06, 2014: Acceleron Announces New Clinical Data Presentations on sotatercept at the 2014 American Society of Hematology Annual Meeting; Oct 01, 2014: Acceleron to Host Educational Webcast on Luspatercept; Oct 01, 2014: Acceleron to Host Educational Webcast on Beta-thalassemia; Jun 14, 2014: Celgene and Acceleron announces interim data from ACE-536 at the 19th European Hematology Association annual congress; Jun 14, 2014: Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia.

Explore more reports on Hematology Therapeutics at

More reports on Global Market Direct Publisher Reports:

H3N2 Infection - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for H3N2 Infection. Companies discussed in this report include AlphaVax, Inc., Colby Pharmaceutical Company, Crucell N.V., Cure Lab, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, NanoViricides, Inc., REPLICor Inc., Takeda Pharmaceutical Company Limited, Vaxart, Inc.

Cough - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Cough. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include Afferent Pharmaceuticals, Inc., Ahn-Gook Pharmaceutical Co., Ltd., Alitair Pharmaceuticals, Inc., Ario Pharma Ltd, AUS Bio Limited, Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., Bharat Biotech International Limited, Biological E. Limited, Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, DBV Technologies S.A., GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Green Cross Corporation, Hanmi Pharmaceuticals, Co. Ltd., Hydra Biosciences, Inc., Hyundai Pharmaceutical Co., Ltd., Indian Immunologicals Limited, LG Life Sciences, Ltd., NanoBio Corporation, Neos Therapeutics, Inc., Novartis AG, Orbis Biosciences, Inc., Panacea Biotec Limited, Sanofi, Sanofi Pasteur SA.

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Mar 26, 2015
Previous Article:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025.
Next Article:Mountain Province Diamonds Announces Completion of Primary Syndication of US$370M Term Loan Facility.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters